Research programme: HIV-1 protease inhibitors - Rottapharm|Madaus

Drug Profile

Research programme: HIV-1 protease inhibitors - Rottapharm|Madaus

Alternative Names: BRU-83-92

Latest Information Update: 08 Nov 2014

Price : $50

At a glance

  • Originator Rottapharm Madaus
  • Class Peptides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 08 Nov 2014 Preclinical development is ongoing in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top